Generated June 2, 2026 at 10:38 AM ET
· Covers June 2 trading day
· 10 of 91 ready 8-Ks selected
· AI-assisted overview
The day featured multiple M&A and divestiture announcements, including Wiley's $452M all-cash acquisition of Emerald Publishing, ESAB's completion of its $1.45B purchase of Eddyfi Technologies, and Onity Group receiving regulatory approval for a reverse mortgage asset sale expected to yield $70-80M in proceeds. Regulatory actions were mixed: Cingulate received a Complete Response Letter for its ADHD drug CTx-1301 due to CMC-only issues, while MannKind's Afrezza was approved for pediatric diabetes patients aged 6 and older, and Vera Therapeutics disclosed FDA alignment on an earlier eGFR analysis for atacicept. Celcuity reported positive Phase 3 data for gedatolisib in breast cancer, showing a doubling of progression-free survival. Other material events included Picard Medical's termination of its CFO, Dragonfly Energy's trade libel lawsuit, and INVO Fertility's announcement of a financial restatement due to accounting errors in prior periods.
leadership
negative
materiality 0.70
June 2, 2026, 6:29 AM ET
Picard Medical terminates CFO Bernard Skaggs; appoints Georgina Smith as CAO
- Bernard Skaggs terminated as CFO, effective June 1, 2026.
- Georgina Smith, 54, appointed Chief Accounting Officer, effective same date.
- Smith previously served as Controller of SynCardia Systems, a Picard subsidiary.
regulatory
negative
materiality 0.85
June 2, 2026, 8:10 AM ET
Cingulate receives FDA Complete Response Letter for CTx-1301; no safety/efficacy issues, CMC-only
- FDA issued a Complete Response Letter for CTx-1301 (dexmethylphenidate HCl) NDA for ADHD.
- No current concerns about clinical safety or efficacy; CMC information requests identified.
- Company expects prompt resubmission of requested CMC data; has ~$30M cash on hand.
WLY
JOHN WILEY & SONS, INC.
M&A
positive
materiality 0.85
June 2, 2026, 8:30 AM ET
Wiley acquires Emerald Publishing for $452M; adds ~500 journals, expected accretive in year one
- Purchase price of £337.5M (~$452M) all-cash; funded from cash on hand.
- Emerald generates >$85M revenue, 92% recurring, mid-single-digit growth.
- Expected accretive to adjusted EPS in year one; ~7x EV/EBITDA including ~$30M cost synergies by year three.
M&A
positive
materiality 0.80
June 2, 2026, 6:45 AM ET
Onity receives regulatory approval for reverse mortgage asset sale to FAR; expects $70-80M proceeds
- Regulatory approval received May 28 for sale of reverse MSRs on ~20,000 loans ($5.1B UPB) to Finance of America Reverse.
- Expected net proceeds of $70-80M based on April 30 book value; Onity will subservice the portfolio for three years.
- Upon closing, Onity will discontinue reverse originations and FAR will acquire the reverse loan pipeline.
M&A
positive
materiality 0.80
June 2, 2026, 6:41 AM ET
ESAB completes $1.45B acquisition of Eddyfi Technologies
- Acquired Eddyfi for $1.45 billion in cash, subject to customary working capital adjustments.
- Financed with cash on hand, 5.625% senior notes due 2031, $175M Series A Mandatory Convertible Preferred Stock, and $143M common stock private placements.
- Series A Mandatory Convertible Preferred Stock carries 6.50% cumulative dividend and mandatory conversion into common after ~3 years at rates between 7.1806 and 8.2576 shares per $1,000.
regulatory
positive
materiality 0.75
June 2, 2026, 8:00 AM ET
FDA approves Afrezza for pediatric diabetes patients ages 6+
- FDA approved supplemental BLA for Afrezza (insulin human) Inhalation Powder for children and adolescents aged 6 and older with type 1 and type 2 diabetes.
- More than 350,000 U.S. children and adolescents live with diabetes; majority have type 1 and require lifelong insulin.
- Approval fulfills the last postmarketing requirement from the original June 27, 2014 approval letter.
VERA
Vera Therapeutics, Inc.
regulatory
positive
materiality 0.75
June 2, 2026, 7:05 AM ET
Vera Therapeutics announces FDA alignment on earlier eGFR analysis for atacicept; results expected Q3 2026
- FDA agreed to revised ORIGIN 3 eGFR analysis plan to support potential full approval of atacicept in IgA Nephropathy.
- eGFR results now expected in the third quarter of 2026.
- Company plans to submit supplemental Biologics License Application for full approval in Q4 2026.
DFLI
Dragonfly Energy Holdings Corp.
litigation
negative
materiality 0.55
June 2, 2026, 7:45 AM ET
Dragonfly Energy files trade libel suit over alleged false battery tests
- Lawsuit filed June 1, 2026 in Nevada state court against William Errol Prowse IV and Prowse Publications LLC.
- Alleges Prowse removed structural components and used damaged batteries in tests, then published false statements.
- Seeks damages and injunctive relief for financial and reputational harm to Battle Born Batteries brand.
other material
positive
materiality 0.85
June 2, 2026, 8:10 AM ET
Gedatolisib doubles PFS vs alpelisib in PIK3CA mutant HR+/HER2- ABC Phase 3 trial
- Gedatolisib-triplet reduced risk of progression or death by 50% (HR=0.50; p<0.0001); median PFS 11.1 vs 5.6 months.
- ORR 48.9% for triplet vs 26.0%; median DOR 15.7 vs 7.5 months for alpelisib+fulvestrant.
- Grade 3+ TRAEs: neutropenia 58.8% (triplet) vs 0.7%; discontinuation rate 2.6% vs 7.1%.
other material
negative
materiality 0.75
June 2, 2026, 8:30 AM ET
INVO Fertility restates 2025 Q1-Q3 financials; non-reliance due to accounting errors
- Non-reliance on unaudited 10-Qs for Q1-Q3 2025 due to errors in derivative, debt extinguishment, and preferred stock classification.
- Errors do not impact revenue or operations; limited to asset, liability, equity, and net income line items.
- Restatement to be included in the 2025 Form 10-K; historical amounts will be recast in future filings.